Future Frontiers in Stroke Care: Biomarkers, Adherence, and Novel Therapies

This episode, titled ‘Future Frontiers in Stroke Care: Biomarkers, Adherence, and Novel Therapies,’ features neurology experts who discussed the following critical questions:

What are the strengths and limitations of current treatment regimens used to prevent recurrent ischemic stroke?

Which biomarkers are most associated with non-cardioembolic stroke and do they currently have a role in clinical management?

Describe the unmet needs for novel therapies to prevent non-cardioembolic ischemic stroke.

Led by the moderator, the neurology experts examined the current clinical landscape of secondary prevention, noting the high quality of data for short-term dual antiplatelet therapy (DAPT) but highlighting the rising bleeding risks that occur after the 90-day mark. David Rose discussed recent 2023 research into molecular signatures and biomarkers—such as homocysteine and renal markers—that may eventually allow for more precise risk stratification in non-cardioembolic stroke. The panel highlighted the significant unmet need for durable, long-term prevention strategies that do not carry the prohibitive bleeding risks associated with traditional anticoagulants. Furthermore, the conversation looked toward a future of "precision neurology," where safer therapies and longer-acting agents could overcome current barriers of patient adherence and the fear of intracranial hemorrhage.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, ‘The Emerging Role of Factor XIa Inhibition in Stroke Prevention,’ panelists will continue their discussion on ischemic stroke and highlight the clinical rationale for investigating Factor XIa inhibitors and the different agents currently in clinical development.